NOVEL RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS DETERMINATION OF LECITHIN AND SILYMARIN
HTML Full TextNOVEL RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS DETERMINATION OF LECITHIN AND SILYMARIN
Sufiyan Ahmad *, Jagdish Pawar and Tanvir Shaikh
Department of Quality Assurance, Gangamai College of Pharmacy, Nagaon, Dhule, Maharashtra, India.
ABSTRACT: Objective: A simple, rapid, accurate, precise and reproducible validated RP- HPLC method was developed for the determination of Lecithin and Silymarin in bulk and tablet dosage forms. Methods: A simple double beam UV spectrophotometric method has been developed and validated with different parameters such as linearity, precision, repeatability, the limit of detection (LOD), Limit of Quantification (LOQ), accuracy as per ICH guidelines. Results: The quantification was carried out using Symmetry PremsilC18 (250mm x 4.6mm, 5µm) column run in an isocratic way using mobile phase comprising of acetonitrile: water (0.1% OPA with PH 3) 70:30 v/v and a detection wavelength of 236 nm and injection volume of 20µL, with a flow rate of 1ml/min. The retention times of Lecithin and Silymarin were found to be 6.58 min and 3.616min. The method was validated in terms of linearity, precision, accuracy, LOD, LOQ, and robustness in accordance with ICH guidelines. The assay of the proposed method was found to be 99-101%. The recovery studies were also carried out, and the mean % recovery was found to be 99-101%. The % RSD from reproducibility was found to be <2%. Conclusion: The proposed method was statistically evaluated and can be applied for routine quality control analysis of Lecithin and Silymarin in bulk and in the tablet dosage form.
Keywords: Lecithin and Silymarin, Method development, Validation, Simultaneous estimation, RP- HPLC
INTRODUCTION: Lecithin (LCN) is chemically (2-nonanoyloxy – 3 – octadeca - 9, 12 - dienoyloxy propoxy) - [2-(trimethyl - azaniumyl) ethyl] phosphinate Fig. 1 and Lecithin is used for treating memory disorders such as dementia and Alzheimer’s disease. It is also used for treating gallbladder disease, liver disease, certain types of depression, high cholesterol, anxiety, and a skin disease called eczema 1. Silymarin (SYL) is chemically 3, 5, 7- trihydroxy-2- [3-(4-hydroxy-3-methoxy phenyl) -2-(hydroxyl methyl) -2, 3-dihydro-1, 4-benzodioxin-6-yl]-2, 3-dihydro-chromen-4-one Fig. 1 and Silymarin is a natural polyphenolic flavonoid derived from milk thistle seeds. It has long been used as a traditional herbal hepatoprotective agent. It is one of the most widely used flavonoids compounds because of its extensive therapeutic properties 2.
Recently, there has been a growing interest in using herbal medicines to treat skin disease 3-5. The literature review reveals that no HPLC methods for the estimation of Lecithin and Silymarin in tablet dosage. Hence the present study develops an accurate and reliable RP- HPLC method for simultaneous estimation of Lecithin and Silymarin in tablet dosage form as per ICH norm.
FIG. 1: STRUCTURE OF LECITHIN AND SILYMARIN
MATERIALS AND METHODS:
Materials and Reagents: The drug analysis was carried out on Agilent (S. K.) Gradient System UV Detector. Equipped with Reverse Phase (Grace) C18 column (4.6mm x 250mm; 5µm), an SP930D pump, a 20µl injection loop, and UV730D Absorbance detector and running autochro-3000 software.
The API of both drugs Lecithin and Silymarin procured from R. S. I. T. C Jalgaon, India. Orthophosphoric acid (OPA) (HPLC grade Avantor Performance material India Ltd. Thane, (Maharashtr). Methanol, acetonitrile, water (HPLC grade Merck Specialties Pvt. Ltd. Shiv Sager Estate ‘A’ Worli, Mumbai.), 0.45µm filter (Millipore, Bangalore). A combination of Lecithin 525mg and Silymarin 140mg in tablet formulation was procured from a local pharmacy (Shamliv Tab, Shalman pharmaceuticals Pvt. Ltd. Gujarat.
Chromatographic Conditions: The analysis of the drug was carried out on Agilent (S.K.) Gradient System UV Detector. Equipped with Reverse Phase (Agilent) C18 column (4.6mm x 100mm; 2.5µm), a SP930Dpump, a 20µl injection loop, and UV730D (DAD) Absorbance detector and running Chemstation software. Temperature ambient 26 0C; sample size 20 µl; mobile phase MeOH: Water (0.1% with OPA) 70: 30; detection wavelength 236 nm; flow rate 1ml/min.
Preparation of Standard Stock Solution:
Preparation of Std. Silymarin Solution: (Stock -I): An accurately weighed quantity, 10 mg of Silymarin (SYL) was dissolved in methanol in a 10 ml volumetric flask and volume made up to 10.0 ml to produce a solution of 1000 µg/ml. From the freshly prepared standard stock solution (1000 µg/ml), 0.1ml stock solution was pipette out in 10 ml of a volumetric flask, and volume was made up to 10 ml with mobile phase to get a final concentration of 10 µg/ml.
Preparation of Std. Lecithin Solution: (Stock-II): An accurately weighed quantity, 3.75 mg of Lecithin (LCN) was dissolved in methanol in 10 ml volumetric flask and volume made up to 10.0 ml to produce a solution of 40 µg/ml. From the freshly prepared standard stock solution (3750 µg/ml), 0.1 ml stock solution was pipette out in 10 ml of the volumetric flask, and volume was made up to 10 ml with mobile phase to get a final concentration of 0.4µg/ml.
Preparation of std. Silymarin and Lecithin solution: (Stock III): From the freshly prepared standard stock solution (1000 and 3750 µg/ml), 0.1 ml stock solution was pipette out in 10 ml of the volumetric flask, and volume was made up to 10 ml with mobile phase to get final concentration 10– 50 and 37.5 – 187.5 µg/ml Fig. 2.
FIG. 2: CHROMATOGRAM OF STANDARD COMBINATION OF LCN AND SYL
Method Development and Validation: The working standard of various concentrations was prepared by taking aliquots of standard solution and diluting to get the required concentration for calibration plot and injecting 6-10.
Assay Preparation for Commercial Formulation: Weigh 20 Lecithin and Silymarin combination tablets, calculate the average weight, and accurately weigh and transfer the sample equivalent to 10 mg Lecithin and 37.5mg Silymarin into 10 ml volumetric flask.
Add about 10ml MEOH of diluent and sonicate to dissolve it completely and make volume up to the mark with diluent. Mix well and filter through a 0.45 µm filter. Further pipette 0.1ml of the above stock solution into a 10 ml volumetric flask and dilute up to the mark with diluents (10 µg/ml). The simple chromatogram of test Lecithin and Silymarin is shown in Fig. 3.
The amounts of Lecithin and Silymarin per tablet were calculated by extrapolating the area value from the calibration curve.
The analysis procedure was repeated five times with tablet formulation. Tablet Assay for %Label claim for % RSD Calculated, result was shown in Table 1.
FIG. 3: CHROMATOGRAM FOR MARKETED FORMULATION
TABLE 1: ANALYSIS OF MARKETED FORMULATION
Drug | RT [min] | Area [mV*s] | Area% | TP | TF | Resolution |
Lecithin | 3.1833 | 784.4373 | 54.47 | 4128.5 | 1.4000 | 0.0000 |
Silymarin | 7.3667 | 615.5257 | 45.53 | 10833.3 | 1.1111 | 14.7647 |
RESULTS:
Linearity and Range: The data obtained in the calibration experiments when subjected to linear regression analysis showed a linear relationship between peak areas and concentrations in the range 37.5-187.2 µg/ml for Lecithin and 10-50µg/ml for Silymarin Table 2 and 3 depict the calibration data of Lecithin and Silymarin. The respective linear equation for Lecithin was y = 71.605x + 55.119 and Silymarin equation y = 16.549 x + 0.5469 where x is the concentration and y is area of peak. The correlation coefficient was 0.999. The calibration curve of Lecithin and Silymarin is depicted in Fig. 4 and 5.
TABLE 2: LINEARITY DATA FOR LECITHIN
Method | Conc.
µg/ml |
Peak area (µV.sec) | Average peak area (µV. sec) | S.D. of peak area | % RSD of peak area | |
1 | 2 | |||||
RP-HPLC Method | 37.5 | 623.5154 | 600.2597 | 611.8876 | 16.44 | 2.69 |
75 | 1220.399 | 1298.359 | 1259.379 | 55.13 | 4.38 | |
112.5 | 1819.49 | 1902.357 | 1860.924 | 58.60 | 3.15 | |
150 | 2441.527 | 2498.368 | 2469.947 | 40.19 | 1.63 | |
187.2 | 3050.95 | 3168.265 | 3109.607 | 82.95 | 2.67 | |
Equation | y = 16.549 x + 0.5469 | |||||
R2 | 0.999 |
TABLE 3: LINEARITY DATA FOR SILYMARIN
Method | Conc.
µg/ml |
Peak area(µV.sec) | Average peak area (µV.sec) | S.D. of Peak Area | % RSD of Peak Area | |
1 | 2 | |||||
RP-HPLC Method | 10 | 775.2776 | 788.365 | 781.8213 | 9.25 | 1.18 |
20 | 1470.337 | 1459.327 | 1464.832 | 7.79 | 0.53 | |
30 | 2202.554 | 2165.296 | 2183.925 | 26.34 | 1.21 | |
40 | 3008.865 | 2956.354 | 2982.609 | 37.13 | 1.24 | |
50 | 3638.126 | 3568.265 | 3603.195 | 49.40 | 1.37 | |
Equation | Y= 71.605 x + 55.119 | |||||
R2 | 0.999 |
FIG. 4: CALIBRATION CURVE OF LECITHIN
FIG. 5: CALIBRATION CURVE OF SILYMARIN
Accuracy: It is defined as the closeness of agreement between the actual (true) value and analytical value and obtained by applying the test method a number of times.
The accuracy of the methods was determined at three different concentration levels, i.e., 80%, 100%, and 120% Fig. 6 - 8 in triplicate for each drug as per ICH guidelines.
From the total amount of drug found, the percentage recovery was found in a range of 99-101% Table 4 and 5.
TABLE 4: RESULT OF RECOVERY DATA FOR LECITHIN AND SILYMARIN
Drug | Level (%)
|
Amt. taken (μg/ml) | Amt. Added
(μg/ml) |
Absorbance
Mean* ± S.D. |
Amt. recovered Mean *±S.D. | %Recovery
Mean *± S.D. |
SLY
|
80% | 10 | 8 | 18.02±0.021 | 8.02±0.021 | 100.333±0.26 |
100% | 10 | 10 | 19.98±0.007 | 20.58±0.007 | 99.80±0.007 | |
120% | 10 | 12 | 21.96±0.022 | 20.58±0.022 | 99.67±0.18 | |
LCN | 80% | 75 | 60 | 135.29±0.69 | 60.29±0.69 | 100.48±1.14 |
100% | 75 | 75 | 150.33±0.15 | 20.58±0.15 | 100.44±0.20 | |
120% | 75 | 90 | 164.42±0.59 | 20.58±0.59 | 99.36±0.66 |
*Mean of each 3 reading for RP-HPLC method
TABLE 5: STATISTICAL VALIDATION OF RECOVERY STUDIES LECITHIN AND SILYMARIN
Method | Level of Recovery (%) | Drug | % RSD | S.D.* | Mean % Recovery |
RP-HPLC Method
|
80% | SYL | 0.26 | 0.26 | 100.33 |
LCN | 1.14 | 1.14 | 100.48 | ||
100% | SYL | 0.07 | 0.07 | 99.80 | |
LCN | 0.20 | 0.20 | 100.44 | ||
120% | SYL | 0.18 | 0.18 | 99.67 | |
LCN | 0.66 | 0.66 | 99.36 |
*Denotes average of three determinations for RP-HPLC
FIG. 6: CHROMATOGRAM OF ACCURACY 80%
FIG. 7: CHROMATOGRAM OF ACCURACY 100%
FIG. 8: CHROMATOGRAM OF ACCURACY 120%
Precision: Precision was studied to find out intra and inter-day variations in the test method of Lecithin and Silymarin.
Intra‐day precision was determined by analyzing three concentrations in three replicate measurements of within the linearity range of drugs three different times in the same day.
Inter‐day precision was conducted during routine operation of the system over three consecutive days. Intraday and Inter day Precision studies on RP- HPLC method for Lecithin and Silymarin, which shows the high precision % amount in between 97% to 101%, indicates the analytical method that concluded Table 6.
TABLE 6: INTRADAY AND INTER DAY PRECISION STUDIES ON HPLC METHOD FOR LCN AND SYL
Drug | Conc. (µg/ml) | Interday Precision | Intraday Precision | ||
Mean± SD | %Amt Found | Mean± SD | %Amt Found | ||
SYL |
10 | 9.89±0.96 | 98.93 | 10.00±0.65 | 100.00 |
15 | 15.37±0.11 | 102.51 | 15.45±0.28 | 102.05 | |
20 | 19.76±0.15 | 98.80 | 19.87±0.14 | 99.38 | |
LCN |
75 | 105.55±0.9 | 99.82 | 105.41±0.65 | 99.69 |
112.5 | 161.51±0.8 | 102.39 | 161.02±0.73 | 101.44 | |
150 | 209.37±0.17 | 98.84 | 209.37±0.17 | 98.84 |
Mean of each 3 reading for HPLC method
Limit of Detection (LOD) and Limit of Quantification (LOQ): LOD is the lowest analyte in a sample that can be detected but not necessarily quantified under the stated experimental conditions.
LOQ is the lowest concentration of analyte in a sample that can be determined with acceptable precision and accuracy under stated experimental conditions.
The LOD and LOQ of Lecithin were found to be 0.033 μg/ml and 0.01μg/ml, the analytical method.
The LOD and LOQ of Silymarin were found to be 0.2375μg/ml and 0.7199 μg/ml, the analytical method that concluded.
Robustness: The robustness is a measure of its capacity to remain unaffected by small and deliberate variations in method parameters and provides an indication of its reliability during normal usage; hence the following are performed by slight variations in parameters. The assay content of the sample was measured by the change in the flow rate 0.6ml/min to 0.8ml/min Table 7.
TABLE 7: RESULT OF ROBUSTNESS STUDY
Parameters
|
Conc.
(µg/ml) |
Amount of detected
(mean ±SD) |
% RSD | Amount of detected
(mean ±SD) |
%RSD |
For Lecithin | For Silymarin | ||||
Chromatogram of flow change 0.9 ml | 50+187.2 | 1296.26± 1.61 | 0.12 | 1689.44± 1.16 | 0.07 |
Chromatogram of flow change 1.1 ml | 50+187.2 | 969.58±1.39 | 0.14 | 1260.09±2.11 | 0.17 |
Chrom. of comp change wavelength change 235nm | 50+187.2 | 1247.9±1.50 | 0.12 | 1674.5±1.24 | 0.07 |
Chrom. of comp change wavelength change 237nm | 50+187.2 | 975.56±1.45 | 0.15 | 1233.80±2.49 | 0.20 |
Chrom. of mobile phase change 69+31 ml | 50+187.2 | 1673.9±0.64 | 0.47 | 1447.2±0.41 | 0.03 |
Chrom. of mobile phase change 71+29 ml | 50+187.2 | 1108.46±2.51 | 0.23 | 1448.21±2.84 | 00.20 |
Repeatability: Repeatability studies on RP-HPLC method for Lecithin and Silymarin were found to be, the % RSD was less than 2%, which shows high percentage amount found in between 98% to 102% indicates the analytical method that concluded Table 8.
TABLE 8: REPEATABILITY STUDIES ON RP-HPLC FOR LECITHIN AND SILYMARIN
Method | Conc. of LCN and SYL (mg/ml) | Peak area | Amount found (mg) | % amount found |
HPLC SYL Method | 20 | 42.47 | 19.78 | 98.90 |
20 | 43.11 | |||
Mean | 42.80 | |||
SD | 0.45 | |||
%RSD | 0.16 | |||
150 | 209.06 | 148.07 | 98.71 | |
HPLC LCN Method | 150 | 208.88 | ||
Mean | 208.98 | |||
SD | 0.12 | |||
%RSD | 0.16 |
DISCUSSION: The proposed methods for simultaneous estimation of LCN and SYL in tablet dosage forms were found to be simple, accurate, economical and rapid. The method was validated as per the ICH Q2 (R1) guidelines. Standard calibration curves for LCN and SYL were linear with correlation coefficients (r2) values in the range of the selected wavelengths, and the values were average of three readings. The values of % RSD are within the prescribed limit of 2%, showing high precision of methods, and recovery was close to 101% for both the drugs. The analysis of pharmaceutical formulations reveals that the proposed methods are suitable for their simultaneous determination with virtually no interference of usual additive present in pharmaceutical formulations. Hence, the above methods can be applied successfully to estimate LCN and SYL in formulations simultaneously.
CONCLUSION: Simple, rapid, accurate and precise RP-HPLC methods have been developed and validated for the routine analysis of LCN and SYL in API and tablet dosage forms. The developed methods are recommended for routine and quality control analysis of the investigated drugs in two-component pharmaceutical preparations.
The amount found from the proposed methods was in good agreement with the label claim of the formulation. Also the value of standard deviation and coefficient of variation calculated were satisfactorily low, indicating the suitability of the proposed methods for the routine estimation of tablet dosage forms.
ACKNOWLEDGEMENT: The authors are thankful to the Principal, Gangamai College of Pharmacy, Nagaon, Dist. Dhule for providing necessary facilities for research work. They are also grateful to R. S. I. T. C. Jalgaon for giving gift samples of pure drugs.
CONFLICTS OF INTEREST: Authors have no conflicts of interest to declare.
REFERENCE:
- Fatma M Mady, Hanaa Essa, Tarek el-ammawi, Hamdy Abdelkader and Amal K Hussein: Formulation and clinical evaluation of Silymarin pluronic-lecithin organogels for treatment of atopic dermatitis. Drug Design Development and Therapy 2016; 10: 1101-1110.
- Dehmlow C, Erhard J and de Groot H: Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996; 23(4): 749-754.
- Zhao J, Lahiri-Chatterjee M, Sharma Y and Agarwal R: Inhibitory effect of a flavonoid antioxidant silymarin on benzoyl peroxide-induced tumor promotion, oxidative stress and inflammatory responses in SENCAR mouse skin. Carcinogenesis 2000; 21(4): 811-816.
- Gazak R, Walterova D and Kren V: Silybin and Silymarin - new and emerging applications in medicine. Curr Med Chem 2007; 14(3): 315-338.
- Singh RP and Agarwal R: Cosmeceuticals and Silibinin. Clin Dermatology 2009; 27(5): 479– 484.
- ICH–Guidelines Q2A, Validation of Analytical Procedures: Definition and terminology (CPMP III/5626/94) March (1995) Geneva, Switzerland. ICH –Guidelines Q2B, Validation of Analytical Procedures: Methodology, (CPMP/ICH/281/95) November (1996) Geneva, Switzerland.
- Carstensen JT and Rhodes CT: Drug Stability Principles and Practices, 3rd edition, Dekkar Series.
- Ahmad S and Usman RM: Analytical method development and validation for the simultaneous estimation of lamivudine and zidovudine by RP- HPLC in bulk and tablet dosage forms. Journal of Advanced Pharmacy Education & Research 2017; 7(2): 66-71.
- Sufiyan Ahmad, Md. Rageeb Usman, Tanvir Shaikh, Md. Imran and Rashid Akhtar: development and validation of UV spectrophotometric method for estimation of saxagliptin and dapagliflozin in bulk and dosage form. Inter J of Pharma Sci and Res 2021; 12(4): 2185-2192.
- Suresh Mali, Sufiyan Ahmad and Shastry VM: Development and validation of UV visible spectrophotometric method for estimation of aceclofenac and tramadol in bulk and dosage form. International J of Pharma Sciences and Research 2018; 9(9): 3852-3857.
How to cite this article:
Ahmad S, Pawar J and Shaikh T: Novel RP-HPLC method development and validation for simultaneous determination of lecithin and silymarin. Int J Pharm Sci & Res 2022; 13(7): 2710-16. doi: 10.13040/IJPSR.0975-8232.13(7).2710-16.
All © 2022 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.
Article Information
17
2710-2716
629 KB
717
English
IJPSR
Sufiyan Ahmad *, Jagdish Pawar and Tanvir Shaikh
Department of Quality Assurance, Gangamai College of Pharmacy, Nagaon, Dhule, Maharashtra, India.
sufipharm1712@gmail.com
05 November 2021
26 December 2021
06 January 2022
10.13040/IJPSR.0975-8232.13(7).2710-16
01 July 2022